PURPOSE: This prospective randomized trial in extensive untreated @entity978 was undertaken to assess the potential benefit of augmented therapy (12 months chemotherapy or radiation to known disease) compared to standard 6 months chemotherapy. @entity1 AND METHODS: A total of 258 @entity1 , mostly Stage IV, were randomized to four treatment regimens consisting of six cycles of @entity11770 , @entity5713 , @entity4174 , and @entity229 (CVPP); 12 cycles of CVPP; six cycles of CVPP followed by 25 Gy radiotherapy; or three cycles CVPP, 25 Gy radiotherapy, and three cycles CVPP. RESULTS: Complete remissions were achieved in 65% of all @entity1 . A 58% overall 5-year survival rate was obtained. Relapses in irradiated areas of known disease occurred in only 6% of responding @entity1 . There was, however, no statistical difference in response frequency, disease-free survival, or overall survival among the four regimens. Elderly @entity1 responded less frequently. CONCLUSION: While radiotherapy provided control of local (known) disease, no impact on overall survival was apparent. Likewise, doubling the duration of chemotherapy did not improve response or survival. Augmentation of therapy with either radiotherapy or more chemotherapy in this study was of no benefit compared to the standard 6 months of treatment.

Augmented therapy of extensive XXXX : radiation to known disease or prolongation of induction chemotherapy did not improve survival--results of a Cancer and Leukemia Group B study.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENT'] @entity4174 :: ('MESH:D011344', 'Chemical') :: ['procarbazine'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity11770 :: ('MESH:D008130', 'Chemical') :: ['CCNU'] @entity978 :: ('MESH:D006689', 'Disease') :: ["Hodgkin's disease"] @entity5713 :: ('MESH:D014747', 'Chemical') :: ['vinblastine']
@entity978 :: (MESH:D006689,Disease) :: ['Hodgkin's disease']
